A
Subsidiary of Precisio Biotix Therapeutics
Home
About Us
Corporate Overview
Management Team
Lead Products
Lysins
R&D Pipeline
LysiThru™
R&D Facilities
News
Contact Us
Contact Us
Careers
English
中文
English
News
HOME >>
News
New Publication in Antimicrobial Agents and Chemotherapy: LYSG101 Clears MRSA in Animal Models with No Detectable Resistance
2026-04-30
Precisio Biotix Therapeutics, Inc. (Precisio) Announces Dosing of a First Patient with ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection
2025-07-03
Precisio Biotix Therapeutics, Inc. (Precisio) Announces a Grant for the Discovery of Novel Engineered Lysin Antimicrobials Targeting Bacterial Vaginosis Associated Pathobionts (BV)
2025-06-16
Precisio Biotix Therapeutics Announces Collaboration with Mayo Clinic
2024-03-14
Precisio Biotix Therapeutics Acquires London-Headquartered CC Bio, Adding World-Class Antibacterial Platform and Top Scientists
2024-03-01
Precisio Biotix Therapeutics Expands The US Management Team with The Hiring of Dr. Raymond Schuch
2024-01-23
Phagelux Subsidiary Company Name Change to Lysigen
2021-11-12
Phagelux Staph Lysin Out-licensing Announcement
2021-11-04
LysiThru™ Public Announcement
2021-10-11
本站使用
百度智能门户
搭建
管理登录
English